EuroIntervention · 2018 · 27 citations · 17 references
MedicineCardiologyInternal MedicineCardiovascular PharmacotherapyClinical CardiologyInterventional CardiologyAcute Coronary Syndrome InterventionAcute Coronary SyndromesAntiplatelet TherapyCoronary Artery DiseasePercutaneous Coronary InterventionThrombosisAcute Coronary Syndrome ManagementAntiplatelet Therapy After Percutaneous Coronary InterventionAntithrombotic Therapy After Stent ImplantationCoronary StentingIn-stent ThrombosisPercutaneous Coronary Intervention CareStable Coronary Artery Disease InterventionStent Thrombosis Prevention
AIMS: Polymer-free biolimus-eluting stents (PF-BES) have been shown to be superior to bare metal stents in high bleeding risk (HBR) patients treated with one-month dual antiplatelet therapy (DAPT). However, limited evidence is available on PF-BES in non-HBR patients. We aimed to evaluate the safety and efficacy of PF-BES in all-comer patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with stable coronary artery disease or acute coronary syndromes (ACS) undergoing PCI with PF-BES in routine clinical practice were included in a multicentre, prospective registry. DAPT duration was left to the discretion of the operator. The primary endpoint was the composite of cardiovascular death, myocardial infarction (MI), and definite/probable stent thrombosis (ST) at one year. Overall, 1,104 consecutive patients treated with PF-BES were included at 16 Italian centres. Mean age was 68.7±11.2 years, 77.2% of patients were male, 30% had diabetes, 15.1% had chronic kidney disease, and 40.5% had ACS at baseline. Mean CRUSADE score was 24.1±13.1, and 83.7% of patients did not have high bleeding risk features. At one year, the primary endpoint occurred in 4.1% of patients, cardiovascular death in 2.4%, MI in 1.8%, and definite/probable ST in 1.1%. With respect to efficacy, target lesion revascularisation occurred in 1.2% of patients. CONCLUSIONS: This is the first study providing clinical evidence on the use of PF-BES in all-comer patients irrespective of HBR status. Our findings suggest that PF-BES has a favourable safety and efficacy profile in a real-world clinical setting. Further investigation in randomised clinical trials against new-generation DES is warranted.
17
Clinical End Points in Coronary Stent Trials
Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
Roxana Mehran, Sunil V. Rao, Deepak L. Bhatt et al. · Circulation · 2011 · 4.4K citations
Medicine, Cardiology, Hematology +10
Third universal definition of myocardial infarction
Kristian Thygesen, Burkert Pieske, Steven P. Schulman et al. · European Heart Journal · 2012 · 3.1K citations
Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen et al. · Circulation · 2009 · 991 citations · Full text
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Philip Urban, Ian T. Meredith, Alexandre Abizaid et al. · New England Journal of Medicine · 2015 · 808 citations · Full text